News

The names of the companies and the terms of these agreements have not been disclosed for proprietary reasons. Working with its regional marketing representative, Bioxel is actively securing

The purchase price includes cash and future royalties based on net sales of the acquired products, the amounts of which were not disclosed. The assets to be acquired

These devices represent entirely new platforms to treat heart failure and sudden cardiac death and are the result of a multi-year R&D effort to provide physicians enhanced clinical

The company expects to grant a 30-day option to the underwriters to purchase up to an additional 15% of the shares offered solely to cover over-allotments. All of

Through the acquisition, BD (Becton, Dickinson and Company) gains the scientific leadership and insights of Ger van den Engh, a renowned innovator in flow cytometry. Dr van den

Mr Stanley Wong has resigned as president and CEO of the company, effective as of June 1, 2008. Mr Wong’s resignation was due to personal reasons and was

The trial is designed to assess the safety, tolerability and pharmacokinetics of CCX354 in healthy volunteers in single ascending dose and multiple ascending dose cohorts. Preclinical studies showed

There are three segments to the pivotal trial design. During the first segment of the trial, five non-randomized patients will be treated with Sepet to validate the patient

In his new role, Giancola will lead the global organization to gain further market acceptance and continue the growth of Neuromonics. Prior to joining Neuromonics, Giancola was a